INTERLEUKIN GENETICS INC Form 8-K January 03, 2013

### **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, DC 20549** 

#### FORM 8-K

### **CURRENT REPORT PURSUANT**

TO SECTION 13 OR 15(D) OF THE

#### **SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): January 3, 2013

## Interleukin Genetics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of InCompany)

001-32715 94-3123681

(Commission File Number) (IRS Employer Identification No.)

135 Beaver Street Waltham, MA 02452 (Address of Principal Executive Offices) (Zip Code)

## (781) 398-0700

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8	3.01	Other	Events.
--------	------	-------	---------

On January 3, 2013, Interleukin Genetics, Inc. issued a press release announcing the appointment of Scott Snyder as Chief Marketing Officer. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 9.01. Financial Statements and Exhibits.

- (d) Exhibits.
- 99.1 Press Release dated January 3, 2013.

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERLEUKIN GENETICS, INC.

Date: January 3, 2013 /s/ Eliot M. Lurier Eliot M. Lurier Chief Financial Officer